VBLTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (17 10月 2023 @ 05:00):

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States...

Stats
本日の出来高	5.38M
平均出来高	787 717
時価総額	12.11M
EPS	$0 ( 2024-03-12 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.867
ATR14	$0.0180 (11.61%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Fr Capital Holdings, L.p.	Sell	50 000	Ordinary Shares, par value NIS 0.35 each
2023-12-28	Fr Capital Holdings, L.p.	Sell	21 500	Ordinary Shares, par value NIS 0.35 each
2023-12-29	Fr Capital Holdings, L.p.	Sell	6 000	Ordinary Shares, par value NIS 0.35 each
2023-12-26	Fr Capital Holdings, L.p.	Sell	11 456	Ordinary Shares, par value NIS 0.35 each
2023-12-27	Fr Capital Holdings, L.p.	Sell	20 033	Ordinary Shares, par value NIS 0.35 each

INSIDER POWER
-42.88
Last 32 transactions
Buy: 525 000 \| Sell: 1 196 932

ボリューム相関

長: 0.12 (neutral)

短: -0.68 (moderate negative)

Signal:(31.998) Neutral

Vascular Biogenics Ltd 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Vascular Biogenics Ltd 相関 - 通貨/商品

-0.35
( neutral )

-0.34
( neutral )

0.00
( neutral )

-0.17
( neutral )

-0.75
( moderate negative )

0.34
( neutral )

Vascular Biogenics Ltd 財務諸表

Annual	2022
収益:	$658 000
総利益:	$554 000 (84.19 %)
EPS:	$-0.420

FY	2022
収益:	$658 000
総利益:	$554 000 (84.19 %)
EPS:	$-0.420

FY	2021
収益:	$768 000
総利益:	$403 000 (52.47 %)
EPS:	$-0.685

FY	2020
収益:	$922 000
総利益:	$528 000 (57.27 %)
EPS:	$-0.550

Financial Reports:

No articles found.

Vascular Biogenics Ltd

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.